Eli Lilly registers a pre-approval expanded access program for retatrutide

Eli Lilly has registered a pre-approval expanded access program for retatrutide, its investigational triple-hormone obesity drug. The ClinicalTrials.gov record, NCT07629401, is listed with a status of "Available," which means people who are not enrolled in a clinical trial may be able to gain access to the drug ^[1].

Retatrutide has not been approved by the Food and Drug Administration. Under FDA rules, expanded access — sometimes called compassionate use — is a pathway for patients with serious diseases or conditions who cannot join a clinical trial to obtain a product that is still investigational ^[1]. This record uses the "Individual Patients" category, which allows one patient at a time to receive an unapproved drug, and also covers emergency situations ^[1].

What the record says

The eligibility conditions described in the record are narrow. An adult must have a body mass index of 35 or higher despite being on the highest tolerated dose of an approved therapy, must have two or more serious obesity-related complications, and must have no accessible clinical trial to enroll in.

The process is physician-driven. A treating doctor has to request the drug from Lilly and then obtain authorization from the FDA. Patients cannot apply on their own, and a request being submitted is not the same as a request being granted. Lilly is not obligated to say yes to any individual request.

Several practical details are not in the ClinicalTrials.gov record and are not yet known publicly: how long each review takes, whether patients or insurers are charged anything, how many people Lilly expects to supply, and how long monitoring or follow-up would continue. It is also not known whether Lilly plans to broaden the program later to an "Intermediate-size Population" protocol, which under FDA definitions covers more than one patient with the same condition, or to a Treatment IND, which allows a large, widespread population to receive an investigational drug that is already being developed for marketing for that same use ^[1]. The FDA's public expanded access page was not reachable at the time of writing ^[2].

Why it matters for patients

For most people, the practical effect of this registration is small. Expanded access is designed for individual patients who are out of options and cannot get into a study, not as a general supply channel. The BMI threshold, the requirement of two or more serious complications, and the requirement that an approved drug at the highest tolerated dose has already been tried mean that the pathway is aimed at a small group.

Still, the listing matters for one reason: it is the only legal route to retatrutide in the United States outside of a clinical trial. Products sold online or through gray-market channels as "retatrutide" are not part of this program and are not covered by the FDA authorization process the record describes. The expanded access framework exists precisely because an unapproved drug can only be used outside a trial with regulatory sign-off ^[1].

It is also worth noting what expanded access does not provide. The drug is still investigational, so its full benefit and risk profile has not been established through completed FDA review. Patients who receive a drug this way are not adding data to a randomized trial, which is why the record requires that no accessible trial be available first.

What happens next

The record opened on June 1, 2026 with an "Available" status. Under ClinicalTrials.gov definitions, that status can change to "Temporarily not available" if access pauses, "No longer available" if Lilly closes the program, or "Approved for marketing" if the FDA clears retatrutide for public use ^[1]. No approval date for retatrutide has been announced in these sources.

People interested in either the expanded access route or an active retatrutide trial would need to raise it with a treating clinician, since the request has to come from a physician.